Skip to content
⤶
Skip to footer
⤶
Home
Educational Events
News
Join us
Contact Us
Staff
Search
About
Our Story
Our Mission
The Team
Dr Anna Olsson-Brown
Dr Ricky Frazer
Trudy Guinan
Dr Brent O'Carrigan
Dr Clare Barlow
Dr Kate Young
Alice Tew
Dr Alexandra Johnson
Alison Hodge
Nick Garbutt
Governance
Volunteers
Our supporters and funders
Clinical Support
Immunotherapy Toxicity Guidelines
Patient Information
IO Alert Cards
Consent Forms
Video Resources for Patients
BOPA Drug Monographs for Second-line Agents
Immunotherapy Cardiovascular Complications
MDTs and National Advisory Groups
Haemophagocytic Lymphohistiocytosis (HLH)
Immunotherapy-Neurotoxicity Service
Education
Our Education Ethos
The Immunobuddies Podcast
Immunobuddies Podcast Library
Educational Events
IOCN Webinars & Events
IOCN Education
An Introduction to Immuno-Oncology in Practice
National IO Education Forum
Further Resources
E-Learning & Educational Resources
IOCN Educational Posters and Case Presentations
Policy & Governance
Organisations we work with
Pharmacovigilence
Policy and Governance Resources
Our Policies & Constitution
IOCN Website Disclaimer and Conditions of Use Policy
Research
Service Development
Resources
Service Development Education and Courses
IOCN Service Development Programme
Share: twitter
Share: linkedin
Currently viewing:
Home
Clinical Support
Consent Forms
Consent Forms
Cancer Research UK (CRUK) Consent forms for Systemic Anti-Cancer Treatment (SACT)
Immunotherapy regimens
Atezolizumab
Avelumab
Durvalumab
Ipilimumab
Ipilimumab and Nivolumab
Nivolumab
Pembrolizumab
Immunotherapy combination treatment:
Atezolizumab, Bevacizumab, Caroplatin and Paclitaxel
Atezolizumab, Caroplatin and Etoposide
Avelumab and Axitinib
Carboplatin, Paclitaxel and Pembrolizumab
Carboplatin, Pemetrexed and Pembrolizumab
Cisplatin, Pemetrexed and Pembrolizumab
